An interventional study of Sniff Training Kits in Post-viral Anosmia, Anosmia and Hyposmia, sponsored by University of Virginia. Not yet recruiting at 3 sites in United States. Open to participants aged 10 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of Virginia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Anosmia with a site in United States — 17 open to participants now, 20 under way, 1 of them phase 3. Anosmia · United States.
Among the 59 studies in Anosmia with a site in United States, this one is the 4th largest by planned enrollment of the 43 interventional ones that give a count, is the only one that started in 2027, is one of 19 with no phase, reaches primary completion later than 17 of the 19 other live ones, and was the 58th registered.
180 studies on the registry are indexed under Anosmia; 45 are open to participants now.
Browse Anosmia studies →17 of the 59 studies in Anosmia with a site in United States are open now. Recruiting first, the newest first:
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–65 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 18–65 · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Anosmia studies recruiting now, 14 (45%) set no upper age limit and 9 (29%) stop at 75 or younger; 3 take children under 18; 16 take healthy volunteers.
This study: 10 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 2 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 204 is above the median of 60 across 114 interventional studies indexed under Anosmia.
Median enrollment 51 across the 43 interventional studies, 90 across the 16 observational. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 59 have an industry lead sponsor. The 10 most frequent:
University of Virginia is the lead sponsor of 677 studies on the registry; 139 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.
University of Virginia has 1 study filed under Anosmia — fewer than ten, so there is no comparison to draw.
6 of the studies in Anosmia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04714892National Institute on Alcohol Abuse and Alcoholism (NIAAA)Mechanisms Underlying Individual Variations of Taste and Smell in Obesity | 2026-12-30 |
| NCT05881239Massachusetts General HospitalDigital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD | 2026-12-30 |
| NCT07681973The Cleveland ClinicCognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training | 2026-12-31 |
| NCT06733636Johns Hopkins UniversityScents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults | 2026-12-31 |
| NCT07546617Dartmouth-Hitchcock Medical CenterIn Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 59 studies in Anosmia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn whether a structured smell training program (called "sniff training") can help improve sense of smell and quality of life in people who have experienced a reduced or lost sense of smell following a viral illness (also called post-viral anosmia).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cognitively impaired individuals
Use of the following medications (used within 3 months of enrollment):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomly assigned to Arm 1 will receive sniff training kits containing four inhaler cartridges, with each cartridge containing a different odor (such as lemon, leather, rose, banana, etc). Odor names will be on the cartridges. Participants are instructed to sniff each inhaler cartridge in the morning and evening for 12 weeks. After this initial 12 weeks, participants will receive a new kit which may contain four different odors. These new inhaler cartridges will be sniffed for an additional 12 weeks. At several points in the study, participants will take smell tests or answer questionnaires to assess their ability to smell, their quality of life, and their psychological and neurological health.
Other: Sniff Training Kits
Arm 2 will be identical to Arm 1 with the exception that the inhaler cartridges provided to participants randomly assigned to Arm 2 will not have labels identifying the aroma contained in each cartridge.
Other: Sniff Training Kits
Arm 3 will be identical to Arm 2 with the exception that the inhaler cartridges will not contain the same amount of odor as in the inhaler cartridges used in Arm 2.
Other: Sniff Training Kits
This study will test the ability of a structured smell training protocol (called "sniff training") to improved smell function. Participants will be asked to sniff inhaler cartridges containing different USDA GRAS (generally recognized as safe) odors (such as lemon, leather, strawberry, banana, etc). The amount of odor may differ, and odors may or may not be identified on the inhalers. The inhaler cartridge are provided at no charge to study participants in kits that contain four inhalers each.
Improvement in Odor Perception
The investigators will use a highly-validated psychophysical smell test (the Sniffin' Sticks Extended Test) to assess changes in olfactory perception and their duration. This test is the primary outcome measure. The resulting TDI score reflects performance on three related test components that measure odor detection Threshold, odor Discrimination, and odor Identification. The scale is 0-48, with higher scores indicating greater function. Investigators will also administer another highly-validated psychophysical smell test, the University of Pennsylvania Smell Identification Test (UPSIT). The score on this 40 point test will not be used to determine the primary outcome but will allow direct comparisons to some other studies that used this measure (higher scores indicated greater function).
Time frame: From enrollment to the end-of-study visit at 52 weeks
Improvement in social and emotional loneliness
Patients with smell loss often experience negative changes in mental health, including increased loneliness. The investigators will use the well-validated De Jong Gierveld short scale questionnaire, composed of six questions, to assess changes in the levels of emotional and social loneliness for each participant. Higher scores on the six-point scale indicates greater loneliness.
Time frame: From enrollment to the end-of-study visit at 52 weeks
Improvement in quality of life
Patients with smell loss often experience negative changes in their quality of life. To assess changes in health-related quality of life, the investigators will administer the SF-12v2 Health Survey questionnaire (or alternatively the Child Health Questionnaire for participants younger than 18 years old). The SF12v2 provides summary, norm-based scores for mental and physical components, with scores of 50 corresponding to the US population average. Higher scores indicate better health-related quality of life.
Time frame: From enrollment to the end-of-study visit at 52 weeks
Changes in olfactory-associated quality of life
Patients with smell loss often experience negative changes in their quality of life. To assess changes in quality of life aspects that have been previously shown to be correlated with olfactory function, the investigators will administer the olfactory-salient Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS). Higher scores on this 51 point scale indicate a greater negative impact of olfactory dysfunction on quality of life.
Time frame: From enrollment to the end-of-study visit at 52 weeks
Changes in cognitive function
Several studies have suggested that smell training can improve cognitive function. The investigators will administer the Montreal Cognitive Assessment (MoCA) to measure changes in multiple domains of cognitive function in study participants. The MoCA will only be administered to participants ages 14 years old and up. Higher scores on this 30 point scale indicate better cognitive performance.
Time frame: From enrollment to the end-of-study visit at 52 weeks.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Jan 2027; primary completion for Jul 2031, 54 months later.
Of 50 non-industry interventional studies with no phase under Anosmia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 54 months is above that.
Counting every sponsor, half of 50 studies reached it within 28 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.